Buscar
24/02/2023
Clinical outcomes in patients with atrial fibrillation treated with DOACs in a specialized anticoagulation center: Critical appraisal of real-world data
Moret, C, Acosta-Isaac, R, Mojal, S, Corrochano, M, Jimenez, B, Plaza, M, Souto, JC. Clinical outcomes in patients with atrial fibrillation treated with DOACs in a specialized anticoagulation center: Critical appraisal of real-world data. PLoS One. 2023; 18(2)DOI:10.1371/journal.pone.0279297. PMID:36827286. IF:2.900(Q1/3D).
01/01/2023
Development of a predictive model of venous thromboembolism recurrence in anticoagulated cancer patients using machine learning
Muñoz A.J., Souto J.C., Lecumberri R., Obispo B., Sanchez A., Aparicio J., Aguayo C., Gutierrez D., Palomo A.G., Fanjul V., del Rio-Bermudez C., Viñuela-Benéitez M.C., Hernández-Presa M.Á.. Development of a predictive model of venous thromboembolism recurrence in anticoagulated cancer patients using machine learning. THROMBOSIS RESEARCH. 2023; 228DOI:10.1016/j.thromres.2023.06.015. PMID:37348318. IF:3.700(Q1/3D).
01/08/2022
Pharmacokinetic and clinical improvements after PK-guided switch from standard half-life to extended half-life factor VIII products
Megias-Vericat, JE, Boix, SB, Moreno, RB, Mingot-Castellano, ME, Lopez, MR, Hirnyk, MC, Arranz, JM, Villas, JMC, Guaita, SH, Meda, MM, Jaime, FL, Albo-Lopez, C, Palomero-Massanet, A, Seto, NV, Lecinena, IL, Haro, ARC, Andres, JLP. Pharmacokinetic and clinical improvements after PK-guided switch from standard half-life to extended half-life factor VIII products. THROMBOSIS RESEARCH. 2022; 216DOI:10.1016/j.thromres.2022.06.001. PMID:35696967. IF:7.500(Q1/2D).
01/05/2022
Prevention of venous thromboembolism in hematologic neoplasms: an expert consensus from SEHH-SETH
Gonzalez-Porras, JR, Mateo, J, Gonzalez-Calle, V, Marco, P, Garcia-Gutierrez, V, Reverter, JC, Lecumberri, R. Prevention of venous thromboembolism in hematologic neoplasms: an expert consensus from SEHH-SETH. Clinical & Translational Oncology. 2022; 24(5)DOI:10.1007/s12094-021-02735-1. PMID:34850351. IF:3.400(Q3/6D).